Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

Who May Be Eligible (Plain English)

Who May Qualify: - Japanese adult participants aged 18 years old or older - Physician-reported diagnosis of plaque psoriasis - Newly initiating deucravacitinib or apremilast according to the label - Participants who have signed willing to sign a consent form Who Should NOT Join This Trial: - Participants currently participating in or planning to participate in an interventional clinical trial - Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264) - Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Japanese adult participants aged 18 years old or older * Physician-reported diagnosis of plaque psoriasis * Newly initiating deucravacitinib or apremilast according to the label * Participants who have signed informed consent Exclusion Criteria: * Participants currently participating in or planning to participate in an interventional clinical trial * Patients enrolled in deucravacitinib post-marketing surveillance study (ClinicalTrial.gov ID: NCT05633264) * Previous treatment experience with the treatment of interest (e.g. patients who have history of apremilast will not be eligible to be enrolled in apremilast arm of the study and similar for deucravacitinib)

Treatments Being Tested

DRUG

Deucravacitinib

According to the product label

DRUG

Apremilast

According to the product label

Locations (2)

Mebix. Inc.
Minato-ku, Tokyo, Japan
Fukuoka University Hospital
Fukuoka, Japan